Molecular Partners: Road to IPO and beyond

Date
03.10.2017 18:45 - 21:00
Location
Halle 7, Dornacherstrasse 192, Basel

Patrick Amstutz, CEO and co-founder of Molecular Partners, talks about the exciting story of Molecular Partners and shares lessons learned along the way.

Starting and financing a biotech company is not a piece of cake. But closing partnerships and progressively bigger financing rounds, bringing molecules into clinical development and eventually floating a company on the stock market is even harder. Molecular partners has done all of that. The biotech, which emanated out of research of the University of Zürich, is developing DARPins® therapeutics, a new class of small protein therapeutic agents, with high-specificity, potency and versatility in one therapy. The lead compound is partnered with Allergan and currently in phase III. And in 2014, the company successfully floated on the Swiss Stock Exchange.

Register/Details:

Show All

Events

19.12.2017 08:30 - 15:00

Cybersecurity Day 2017 EPFL SwissTech Convention Center, Route Louis-Favre 2, 1024 Ecublens

Show All

Trainings

Mittwoch, 10. Januar 2018; 18:30 - 20:00 Uhr

Cleveres Preismanagement für Startups Einstein Congress, Berneggstr. 2, St.Gallen

Principal

Partners

Contributors